×
About 21,758 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  8,435 results

Clinical Diagnostic Criteria of Familial Hypercholesterolemia - A Comparison of the Ja...
https://doi.org/10.1253/circj.CJ-20-0901
Circulation Journal : Official Journal of the Japanese Circulation Society; Tada H, Okada H et. al.

Dec 3rd, 2020 - This study is aimed to compare the efficacy of the 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria, which focuses on only 3 essential clinical manifestations, with that of Dutch Lipid Clinic Network (DLCN) FH c...

Coronary plaque burden, plaque characterization and their prognostic implications in fa...
https://doi.org/10.1016/j.atherosclerosis.2020.11.012
Atherosclerosis Pérez de Isla L, Alonso R et. al.

Dec 2nd, 2020 - Heterozygous familial hypercholesterolemia (FH) is associated with premature atherosclerotic cardiovascular disease. Semi-automated plaque characterization (SAPC) by coronary computed tomographic angiography (CTA) provides information regarding co...

Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hyper...
https://doi.org/10.1159/000510527
International Archives of Allergy and Immunology; Pastorello EA, Borgonovo L et. al.

Dec 2nd, 2020 - Allergy to Hymenoptera venom (HV) may lead to life-threatening anaphylaxis. Some of the factors influencing the symptom's severity are still undetermined. The aim of this study was to identify the clinical aspects associated with the most severe r...

The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Child...
https://doi.org/10.1177/0003319720975635
Angiology Karapostolakis G, Vakaki M et. al.

Nov 27th, 2020 - Carotid intima-media thickness (cIMT) has been proposed as an early marker of subclinical atherosclerosis in high risk children. Children with heterozygous familial hypercholesterolemia have greater cIMT than matched healthy controls or their unaf...

Does Management of Lipid Lowering Differ Between Specialists and Primary Care: Insights...
https://doi.org/10.1111/ijcp.13861
International Journal of Clinical Practice; Langer A, Tan M et. al.

Nov 27th, 2020 - We studied whether significant differences in care gaps exist between specialists and PCPs. GOAL Canada enrolled patients with CVD or familial hypercholesterolemia (FH) and LDL-C > 2.0 mmol/L despite maximally tolerated statin therapy. During foll...

see more →

Guidelines  25 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Statin Use and the Site-Specific Risk of Colorectal Cancer in Individuals with Hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS)
https://www.sciencedirect.com/science/article/pii/S0939475319301164?via%3Dihub
Nutrition, Metabolism and Cardiovascular Diseases; Lee,J.,et al

Apr 12th, 2019 - Background and Aims We investigated the association between statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia. Methods and Results This study is based on the National Health Insurance Service-National...

Lipid levels and the risk of hemorrhagic stroke among women
https://n.neurology.org/content/early/2019/04/10/WNL.0000000000007454
Rist,P.,et al

Apr 9th, 2019 - Objective To examine the association between lipid levels and hemorrhagic stroke risk among women. Methods We performed a prospective cohort study among 27,937 women enrolled in the Women's Health Study with measured total cholesterol, low-densit...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of ...
http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
Grundy, S.,et al

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

see more →

Drugs  1,713 results see all →

Clinicaltrials.gov  10,795 results

Clinical Diagnostic Criteria of Familial Hypercholesterolemia - A Comparison of the Ja...
https://doi.org/10.1253/circj.CJ-20-0901
Circulation Journal : Official Journal of the Japanese Circulation Society; Tada H, Okada H et. al.

Dec 3rd, 2020 - This study is aimed to compare the efficacy of the 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria, which focuses on only 3 essential clinical manifestations, with that of Dutch Lipid Clinic Network (DLCN) FH c...

Coronary plaque burden, plaque characterization and their prognostic implications in fa...
https://doi.org/10.1016/j.atherosclerosis.2020.11.012
Atherosclerosis Pérez de Isla L, Alonso R et. al.

Dec 2nd, 2020 - Heterozygous familial hypercholesterolemia (FH) is associated with premature atherosclerotic cardiovascular disease. Semi-automated plaque characterization (SAPC) by coronary computed tomographic angiography (CTA) provides information regarding co...

Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hyper...
https://doi.org/10.1159/000510527
International Archives of Allergy and Immunology; Pastorello EA, Borgonovo L et. al.

Dec 2nd, 2020 - Allergy to Hymenoptera venom (HV) may lead to life-threatening anaphylaxis. Some of the factors influencing the symptom's severity are still undetermined. The aim of this study was to identify the clinical aspects associated with the most severe r...

Ezetimibe - ezetimibe tablet-direct rx
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b57dcdef-894c-4801-e053-2a95a90a7239

Dec 1st, 2020 - Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an a...

Atorvastatin calcium - atorvastatin calcium tablet, film coated-Micro Labs Limited
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e94161c-3360-4fb0-bb3a-048fdc1d137a

Nov 30th, 2020 - Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an...

see more →

News  785 results

Evinacumab, Novel Lipid-Lowerer, Extends Promise in Phase 2 Results
https://www.medscape.com/viewarticle/941043

Nov 15th, 2020 - Treatment with evinacumab, an investigational lipid-lowering drug with a novel mechanism of action, safely led to roughly a halving of LDL cholesterol levels in patients with treatment-refractory hypercholesterolemia in a multicenter, phase 2 stud...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.staging.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Women With Heterozygous FH Less Likely to Receive Treatment
https://www.medscape.com/viewarticle/939392

Oct 18th, 2020 - There are gender differences among patients with heterozygous familial hypercholesterolemia (HeFH) in terms of when the disease is diagnosed, how it is treated, and the levels of low-density lipoprotein (LDL) cholesterol attained, suggest data fro...

Inclisiran Effectively Lowers LDL Across High-risk Settings
https://www.staging.medscape.com/viewarticle/939172

Oct 14th, 2020 - Inclisiran (The Medicines Company) sustainably reduces low-density-lipoprotein (LDL) cholesterol levels across genotypes in heterozygous familial hypercholesterolemia (HeFH) and in the primary prevention setting in high-risk patients, suggest the ...

Inclisiran Effectively Lowers LDL Across High-risk Settings
https://www.medscape.com/viewarticle/939172

Oct 14th, 2020 - Inclisiran (The Medicines Company) sustainably reduces low-density-lipoprotein (LDL) cholesterol levels across genotypes in heterozygous familial hypercholesterolemia (HeFH) and in the primary prevention setting in high-risk patients, suggest the ...

see more →

Patient Education  5 results see all →